logo
Plus   Neg
Share
Email

AstraZeneca To Sublicense Worldwide Rights To Movantik To RedHill Biopharma

British drug major AstraZeneca (AZN,AZN.L) said Tuesday it has agreed to sublicense its global rights to Movantik, a peripherally acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation, to RedHill Biopharma.

As part of the deal, which excludes Europe, Canada and Israel, AstraZeneca will continue to manufacture and supply Movantik to RedHill during a transition period. Earlier in 2015, AstraZeneca entered into a co-commercialisation deal with Daiichi Sankyo for Movantik in the US, which will be transferred to RedHill.

With regards to financial terms of the deal, RedHill will make an upfront payment of $52.5 million to AstraZeneca, upon closing, and a further non-contingent payment of $15 million in 2021.

Meanwhile, profit arising from the upfront payment, after taking a charge for derecognition of the associated intangible asset, and the future payment will be reported in AstraZeneca's financial statements.

The divestment is expected to be complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances. Upon completion, the deal will not impact the Company's financial guidance for 2020, Astrazenenca reported.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT